_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
VIVO
Primary Facts
Diagnostics & Research
Name:
-
Sector:
33.85M
Industry:
32.6
CEO:
Mr. John Kenny
Total Employees:
Small Cap
Our Technological Advancement Rating
Our Rating:
-0.565404038
-1.758908161
Meridian Bioscience, Inc. (XNAS:VIVO) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
MERIDIAN BIOSCIENCE, INC. (XNAS:VIVO)
One Month Price Target:
Six Month Price Target :
$32.65
Likely Price in One Year's Time:
Ticker:
$32.9
Likely Trading Range Today Under (Normal Volatility)
$32.9
Price Upper limit ($) :
$33.2
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P151
This week:
$30.09
This month :
$26.98
Other Primary facts
Market Cap:
43.75M
Market Cap Classification:
1.40B
Number of Shares
IPO Date:
D
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-22.89%
$21.36
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$38.75
22.86%
$26.45
$44.24
Medium risk (<10%) entry points
Buy Call
Sell Call
$35.80
Buy Put:
Sell Put:
$20.96
$29.40
$36.97
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Diagnostics & Research
Sharpe Ratio:
VIVO, is amongst the top 20% highest yielding stocks in terms of daily returns
Comparison:
2.52%
1.563550744
Sharpe ratio is 156.36% higher than the industry
Average Returns/Yield of
Diagnostics & Research
Daily returns:
1
Weekly returns:
0.26%
Monthly returns:
1.30%
Yearly returns:
62.22%
Comparison of returns:
1.228541817
Classification:
Average annual returns/yield (last 3 years) is 122.85% above industry average
Results of T-Test of Returns:
VIVO is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.20
Volatility (measured by Standard Deviation)
Daily Volatility:
& ratio is 183.21% higher than the market/S&P 500 average
Weekly Volatility:
3.88%
Monthly Volatility:
8.67%
Yearly Volatility:
17.35%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
75.61%
-81.97%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -81.97% below long-term volatility
Weekly VaR:
-7.71%
Monthly VaR:
-17.23%
How Much Can the price of
Diagnostics & Research
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Very high (>70%)
Worst case (decline):
$23.64
This translates to price declining to:
-27%
This translates to price declining to:
>85%
Severe Crash Probability
-34.46%
What is Value at Risk (VaR)?
Risk Fundamentals
108.39%
VIVO is a 143.25% riskier investment compared to the market/S&P 500 & is 108.39% riskier than Nasdaq (IXIC)
VIVO is a 143.25% riskier investment compared to the market/S&P 500
Beta Examination of
Diagnostics & Research
0.272
Expected beta in 1 year's time:
0.591
Expected beta in 3 year's time:
0.507
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--0.27
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is -76.98% below industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.242
-0.823
Average Industry Beta:
Beta is -82.32% lower than peers
-0.769831029
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -46.01% below industry mean WACC
-65.21%
Alpha provided | Alpha Analysis
Alpha provided:
0.718
2.430
36.413
Analysis of Cost of Capital of
Diagnostics & Research
Equity cost of capital:
Alpha is 3641% higher than market/& is unsustainably high
-0.554
Unlevered (without debt) cost of capital:
Equity cost of capital is -55.41% below industry mean WACC
Before-tax cost of debt:
4.47%
After-tax cost of debt:
2.85%
Overall debt rating:
2.25%
Weighted average cost of capital (WACC):
2.85%
-46.01%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -55.77% below the industry mean
-61.57%
EPS:
Sixty-One Million Four Hundred Forty Thousand Seven Hundred Fifty Dollars
Expected Annual growth rate of EPS (3Y):
-
25.27%
Free cash flow (FCF) per share:
Price to book ratio is -96.70% below the industry mean
Growth rate in R&D investment/expenditure is -142.60% lower than the industry
54.54239436
Debt per share
Debt repayment rate in last quarter: 15.74%
EBITDA per share
Each employee generates 323% more EBITDA than industry average revenue per employee
Valuation Analysis Today of
Diagnostics & Research
P/E Ratio:
Sustainable growth rate is -65.21% below industry average
P/E Ratio of Competitors/Peers:
33.24
-0.105960392
52.41876488
-0.378085308
$1.85
-
P/S (Price to Sales ratio):
$7.76
-0.557675838
P/B (Price to book value ratio):
Price to sales ratio is -55.77% below the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -61.57% below industry average
-184.42%
Dividend Analysis
Net income growth rate is -184.42% lower than the industry average net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
-4.97%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 9.0 years
Debt to assets ratio:
-3.74%
Net debt to assets ratio:
15.51%
-75.98%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -75.98% below industry average
-3.19
Looking forward:
Debt growth rate:
1.1x
-106.41%
15.74%
Analysis of Key Statistics
Correlation of price movement with the market:
7.353872211
Statistical significance of correlation:
-0.40%
Average Correlation of the industry with the market:
0.271
-44.53%
R Squared (percentage of price movement explained by movement of the market):
0.271
Correlation of price movement with Nasdaq (^IXIC):
0.073
Covariance of price movement with the market:
-0.05
Kurtosis
-0.112
6.948
Skewness of returns:
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
0.037
Fundamental Analysis & Dupont Analysis of
Diagnostics & Research
Gross Profit Margin Ratio:
199.46M
Operating Profit Margin Ratio:
Net profit margin is -116.35% lower than the industry
-121.11%
Net Profit Margin Ratio:
199.46M
Effective Tax Rate:
3.05%
0.116490069
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -105.05% lower than the industry
-13.94%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -121.11% lower than the industry
-105.05%
Financial Leverage:
Interest coverage ratio is -318.65% less than industry average
Current Ratio:
Return on equity (ROE) is -13.94% lower than the industry
-0.179536015
Cash Conversion Cycle (days):
$1.22
0.157733879
Current ratio is -17.95% below industry average
Stock based compensation to net income ratio:
Equity growth rate per share is 5454.24% higher than the industry
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is 15.77% above industry average
0.190771863
EBITDA generated per employee:
Each employee generates 19% more revenue than industry average revenue per employee
3.234012747
Profit generated per employee:
$2.22
410%
Free cash flow (FCF) generated per employee:
Each employee generates 410% more net income/profit than industry average revenue per employee
-21.33391678
Assets/Capital per employee
Each employee generates -2133% less free cash flow than industry average revenue per employee
-21.33391678
Research & Development (R&D) Analysis
0.77%
-1.426006818
Competitors/Peer firms of
Diagnostics & Research
$483.19
OPTIMIZERX CORPORATION (XNAS:OPRX)
VIEWRAY, INC. (XNAS:VRAY)
MESOBLAST LIMITED (XNAS:MESO)
SUTRO BIOPHARMA, INC. (XNAS:STRO)
AMPHASTAR PHARMACEUTICALS INC (XNAS:AMPH)
Connect Biopharma Holdings Ltd (XNAS:CNTB)
IKENA ONCOLOGY, INC. (XNAS:IKNA)
OLEMA PHARMACEUTICALS, INC. (XNAS:OLMA)
Current Analyst Ratings
$1.41
Strong buy�0%
Buy�0%
Hold�21%
Sell�8%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
339.29M
139.82M
234%
24.08M
59.23M
87.70M
28.47M
5.60M
257.20M
- 12.00K
1.59M
16.19M
111%
17.02M
- 1156.00K
90%
17.02M
Statement of Cash Flow
Date:
Period:
15.34M
Differed Income Tax :
4.18M
Stock Based Compensation :
927.00K
Change in Working Capital :
1.90M
Accounts Receivables:
13.85M
Other Working Capital:
1.02M
Other Non-Cash Items:
-
Net Cash Provided by Operating Activities:
- 646.00K
Investments in PP&E:
35.56M
Net Acquisitions:
- 1708.00K
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
12/31/2021
2022
Q1
72.73M
-
72.73M
44.30M
74.20M
12.43M
203.65M
48.72M
114.71M
81.66M
-
8.81M
1.09M
254.99M
-
458.64M
16.29M
2.06M
4.87M
765.00K
30.83M
49.95M
53.53M
2.81M
63.48M
-
113.42M
-
196.04M
555.0K
Value
117.38M
-
345.22M
458.64M
-
55.59M
-
-
-
- 1708.00K
- 10000.00K
-
-
-
- 1087.00K
- 11087.00K
198.00K
22.96M
72.73M
49.77M
35.56M
- 1708.00K
Our Proprietary Portfolio Rating
Our Rating:
-8.423777384
Price Forecast/Expected Price in Next 5 Years of
Diagnostics & Research
2023
2024
2025
2026
2027
449.4295052
$33.37
$457.64
$466.00
$474.52